Analytical Data
-
Gene name
IFI30
- Application
-
Alternative Names
GILT; IP30; Legumaturain; Gamma-Interferon-Inducible Lysosomal Thiol Reductase; Gamma-interferon-inducible lysosomal thiol reductase
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P13284
-
Expression Region
Met1~Lys250
-
Molecular Weight
31kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
IFI30, also known as Interferon-gamma-inducible protein 30, is a crucial member of the family of leukocyte proteins linked to various immune responses and inflammatory processes. This protein is upregulated upon stimulation by interferon-gamma (IFN-γ), which is known for its role in enhancing immune responses against pathogens and tumors. The IFI30 gene encodes for a secreted protein that is involved in the regulation of the immune response, particularly in the maturation of antigen-presenting cells and the modulation of phagocytic activity. Research has shown that IFI30 plays a significant role in the body's defense mechanisms, particularly in the context of infection and autoimmune diseases. Moreover, IFI30 has garnered interest for its potential implications in therapeutic applications; its immunomodulatory properties may contribute to the development of novel treatments for various diseases, including cancer and chronic inflammatory conditions. Recent studies focus on understanding the biochemical properties of the IFI30 protein, its interaction with immune receptors, and its impact on cell signaling pathways. By elucidating the functional roles of IFI30, researchers aim to uncover its potential as a biomarker for disease progression and as a target for innovative immunotherapies. The ongoing investigation into IFI30 and its restructured forms opens new avenues for harnessing its biological functions to enhance immune responses and improve health outcomes in various clinical settings.
